SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets

Shuyu Zheng(University of Helsinki), Wenyu Wang(University of Helsinki), Jehad Aldahdooh(University of Helsinki), Alina Malyutina(University of Helsinki), Tolou Shadbahr(University of Helsinki), Ziaurrehman Tanoli(University of Helsinki), Alberto Pessia(University of Helsinki), Jing Tang(University of Helsinki)
Genomics Proteomics & Bioinformatics
January 24, 2022
Cited by 672Open Access
Full Text

Abstract

Combinatorial therapies have been recently proposed to improve the efficacy of anticancer treatment. The SynergyFinder R package is a software used to analyze pre-clinical drug combination datasets. Here, we report the major updates to the SynergyFinder R package for improved interpretation and annotation of drug combination screening results. Unlike the existing implementations, the updated SynergyFinder R package includes five main innovations. 1) We extend the mathematical models to higher-order drug combination data analysis and implement dimension reduction techniques for visualizing the synergy landscape. 2) We provide a statistical analysis of drug combination synergy and sensitivity with confidence intervals and P values. 3) We incorporate a synergy barometer to harmonize multiple synergy scoring methods to provide a consensus metric for synergy. 4) We evaluate drug combination synergy and sensitivity to provide an unbiased interpretation of the clinical potential. 5) We enable fast annotation of drugs and cell lines, including their chemical and target information. These annotations will improve the interpretation of the mechanisms of action of drug combinations. To facilitate the use of the R package within the drug discovery community, we also provide a web server at www.synergyfinderplus.org as a user-friendly interface to enable a more flexible and versatile analysis of drug combination data.


Related Papers

No related papers found

Powered by citation graph analysis